321 related articles for article (PubMed ID: 30953117)
1. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
Sanchez-Correa B; Lopez-Sejas N; Duran E; Labella F; Alonso C; Solana R; Tarazona R
Cancer Immunol Immunother; 2019 May; 68(5):861-870. PubMed ID: 30953117
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
3. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
5. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
6. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
7. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
10. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
[TBL] [Abstract][Full Text] [Related]
11. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
12. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
13. New insight into cancer immunotherapy.
Escribese MM; Barber D
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
[TBL] [Abstract][Full Text] [Related]
14. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Kean LS; Turka LA; Blazar BR
Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
[TBL] [Abstract][Full Text] [Related]
15. Targeting NK-cell checkpoints for cancer immunotherapy.
Muntasell A; Ochoa MC; Cordeiro L; Berraondo P; López-Díaz de Cerio A; Cabo M; López-Botet M; Melero I
Curr Opin Immunol; 2017 Apr; 45():73-81. PubMed ID: 28236750
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
17. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H; Sun C
Front Immunol; 2019; 10():2354. PubMed ID: 31681269
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
Wang Z; Weiner GJ
J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
